Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report
Danyang Fan,Fuqiu Li,Zhe Liu,Zhanhan Tang,Sha Lv
DOI: https://doi.org/10.2147/ccid.s454057
2024-03-06
Clinical Cosmetic and Investigational Dermatology
Abstract:Danyang Fan, Fuqiu Li, Zhe Liu, Zhanhan Tang, Sha Lv Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, 130000, People's Republic of China Correspondence: Sha Lv, Department of Dermatology, The second hospital of Jilin University, Changchun, Jilin, 130000, People's Republic of China, Email Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic inflammatory disease mainly manifested as skin and osteoarticular lesions. Herein, we describe a female patient with SAPHO syndrome exhibited paradoxical psoriasis and primary palmoplantar pustulosis (PPP) worsened during treatment with adalimumab. We then switched to secukinumab and obtained significant improvement in both skin lesions and osteoarticular pain. These findings suggest that secukinumab might be an appropriate option for patients with SAPHO syndrome who present with TNF-α-inhibitor-induced paradoxical psoriasis. Keywords: SAPHO syndrome, psoriasis, adalimumab, secukinumab Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological and musculoskeletal manifestations. 1 While the pathogenesis of SAPHO syndrome has not been fully elucidated, individual genetic differences, inflammatory factors, and microorganisms might play roles in its mechanism. 2 Notably, Brandao et al identified three enriched exclusive pathways (eEP) associated with extracellular matrix organization in patients with SAPHO syndrome (R-HSA-8941237, R-HSA-2243919, and R-HSA-1474290), suggesting these pathways may be related to the pathogenesis of SAPHO syndrome. 3 Additionally, multiple inflammatory factors, such as TNF-α, IL-1β, IL-8, IL-17, IL-18, are related to SAPHO syndrome, contributing to the complexity of treatment. 4 At present, adalimumab has been used for SAPHO syndrome and showed efficacy in both osteoarticular pain and cutaneous lesions. However, patients might develop psoriasiform rash during treatment with TNF-α inhibitors. These adverse effects lead physicians to select appropriate therapeutic options to treat SAPHO syndrome while alleviating paradoxical cutaneous lesions caused by TNF-α inhibitors. Secukinumab is a fully human IgG1/κ monoclonal antibody which specifically binds to IL-17A and inhibits its interaction with the IL-17 receptor, thereby playing a role in treating IL-17A-mediated inflammatory diseases. Herein, we describe a patient with refractory SAPHO syndrome and TNF-α-inhibitor-induced paradoxical skin lesions, whose cutaneous and osteoarticular symptoms improved without side effects after treatment with secukinumab. A 31-year-old female patient presented with erythema and pustules on the palmoplantar area without obvious causes for 2 months, along with pain in the spine, sternoclavicular joints, and sacroiliac joints for the past 1 month. Medical history revealed that she was diagnosed with palmoplantar pustulosis (PPP) at a local clinic 2 months ago and was given oral glucocorticoids (precise dosage unclear), and her lesions were not in remission. The patient was previously healthy and did not have a history of psoriasis. A dermatological examination revealed that the palms and soles had erythematous patches with well-defined boundaries. Pustules on the surface were partially fused, and obsolete pustules had dried up, with mild desquamation. The palmoplantar psoriasis area and severity index (PPPASI) was 6.6 points and the overall pain intensity score was 6 points according to visual analog scale (VAS). Laboratory tests revealed the following: erythrocyte sedimentation rate, 50 mm/h [normal range <20 mm/h]; C-reactive protein, 19.6 mg/L [normal range <6 mg/L]; human leukocyte antigen-B27, positive; rheumatoid factor, negative; and anti-nuclear antibodies, negative. 99m Tc-methylene diphosphonate whole-body bone scintigraphy revealed inflammatory changes in the osternal angle, bilateral sternoclavicular joints, upper edge of the third lumbar vertebrae, and bilateral sacroiliac joints. The pathological uptake of the anterior chest wall presented the "bull's head" sign. Based on the comprehensive clinical assessment, we diagnosed the patient with SAPHO syndrome (Figure 1a–e). Figure 1 ( a ) Inflammatory changes and the "bull's head" sign in 99m Tc-methylene diphosphonate whole-body bone scintigraphy. ( b – m ) Cutaneous manifestations. Erythema, pustules, and desquamation on the palms ( b and c ) and the left sole ( d ) at baseline. No apparent lesions on the left upper extremity ( e ) at baseline. Severe pustules and crusts on the palms ( f and g ) and the left sole ( h</str -Abstract Truncated-
dermatology